Peter Byrne, NP
Acute Care · Lone Tree, CONPI 1144693532
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Lilly USA, LLC at 45.6% of the total. Among acute care clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 658 payments — averaging $84.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$26K
- AbbVie$21K
- Johnson & Johnson$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$962
- Ardelyx, Inc.$540
- plus $4K from 28 others
What the payments were for
- Consulting fees$4,5008%
- Speaking & faculty fees$29,45053%
- Travel & lodging$7,35113%
- Food & beverage$14,50626%
- Education$840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 93 | $25,509 |
| AbbVie | 226 | $21,027 |
| Johnson & Johnson | 60 | $2,713 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 68 | $1,359 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $962 |
| Ardelyx, Inc. | 13 | $540 |
| Sanofi | 15 | $477 |
| Pfizer | 23 | $371 |
| Bristol Myers Squibb | 19 | $320 |
| Gilead | 14 | $316 |
| Novo Nordisk | 4 | $282 |
| Intercept Pharmaceuticals, Inc. | 9 | $220 |
| QOL Medical, LLC | 11 | $192 |
| Ipsen Biopharmaceuticals, Inc | 11 | $185 |
| Aimmune Therapeutics, Inc. | 9 | $160 |
| Mirum Pharmaceuticals, Inc. | 1 | $145 |
| Amgen | 1 | $132 |
| Regeneron Healthcare Solutions, Inc. | 5 | $125 |
| Janssen Scientific Affairs, LLC | 1 | $118 |
| Ironwood Pharmaceuticals, Inc | 5 | $104 |
| Merck | 4 | $103 |
| Phathom Pharmaceuticals, Inc. | 7 | $96 |
| Nestle Healthcare Nutrition Inc. | 5 | $92 |
| Ferring Pharmaceuticals Inc. | 4 | $72 |
| Boehringer Ingelheim | 3 | $70 |
| Mylan Institutional Inc. | 2 | $38 |
| Redhill Biopharma Inc. | 2 | $32 |
| Celltrion USA Inc. | 1 | $28 |
| Lucid Diagnostics Inc. | 1 | $22 |
| Madrigal Pharmaceuticals | 1 | $19 |
| Organon | 1 | $16 |
| Albireo Pharma, Inc. | 1 | $15 |
| Orphalan Inc | 1 | $15 |
| Braintree Laboratories, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,891 in reported general payments places this provider in the 95th percentile of 239 acute care providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 12 | $105,671 |
| XifaxanRifaximin | 13 | $37,668 |
| LinzessLinaclotide | 23 | $31,171 |
| Budesonide DrBudesonide | 39 | $9,445 |
| PentasaMesalamine | 12 | $6,384 |
| Ursodiol | 28 | $4,227 |
| Colestipol Hcl | 30 | $4,128 |
| Omeprazole | 172 | $3,891 |
| Balsalazide Disodium | 15 | $3,060 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 11 | $1,814 |
| Pantoprazole Sodium | 104 | $1,640 |
| Esomeprazole Magnesium | 15 | $841 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 14 | $718 |
| Dicyclomine Hcl | 32 | $572 |
| Amitriptyline Hcl | 52 | $505 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $220 | $105,67112 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,359 | $37,66813 claims |
| AbbVieLinzess | $21,027 | $31,17123 claims |
| Braintree Laboratories, Inc.Sutab | $14 | $1,81411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 239 acute care providers in Colorado.
Other acute care in Lone Tree
- Tiffany MorganColorado Springs$590K
- Wendy StevensCortez$57K
- Paige YountColorado Springs$26K
- Sarah NorwoodColorado Springs$20K
- Rachele RobertsAurora$19K
- Shari Nieman CorsoLittleton$14K
- Lauren SpitzingerDenver$13K
- Gregory CharlestonPueblo$12K
- Shelley BuntingAurora$11K
- Vladimir LisserHighlands Ranch$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.